全国性研究中测试阴性病例对照与回顾性队列设计评估COVID-19疫苗有效性的比较
该研究在卡塔尔全国人群中使用统一分析策略,比较测试阴性病例对照与回顾性队列设计评估BNT162b2和mRNA-1273初免系列对SARS-CoV-2感染、有症状感染和重症COVID-19的有效性。两种设计对同一疫苗和结局给出相近的疫苗有效性估计,差异主要与对就医行为的处理有关。
要点
- 测试阴性设计中BNT162b2对任何感染有效性71.0%(95%CI 70.1-71.9),队列设计调整检测率后为78.0%(95%CI 77.1-78.9)。
- 两种设计均显示疫苗有效性随时间快速且大致线性衰减,幅度和模式相似。
- 严格实施并使用统一分析策略时,两种观察性设计产生可比的疫苗有效性估计。
核心结论
- 两种设计对同一疫苗和临床相关结局给出大体一致的疫苗有效性估计,差异不大且与就医行为处理有关。
研究设计与样本
- 在卡塔尔2021年1月1日至12月18日开展全国性、匹配的测试阴性病例对照研究和回顾性队列研究,使用统一分析策略。
主要发现
- 测试阴性设计中BNT162b2对任何感染有效性71.0%(95%CI 70.1-71.9),对有症状感染75.6%(95%CI 74.2-77.0),对重症COVID-19 96.3%(95%CI 95.2-97.2)。
- 队列设计调整检测率后,BNT162b2对应有效性分别为78.0%(95%CI 77.1-78.9)、81.2%(95%CI 79.8-82.5)和98.0%(95%CI 96.6-98.8)。
- 两种设计均显示疫苗有效性快速且大致线性衰减,幅度和模式相似;测试阴性设计估计值介于队列设计调整与未调整检测率的估计值之间。
- mRNA-1273观察到类似结果。
临床怎么用
- 在质量数据基础上采用统一分析策略时,测试阴性病例对照与回顾性队列设计均可用于疫苗有效性评估并给出可比结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Observational studies are central to assessing vaccine effectiveness and informing public health policy. The two most common designs are test-negative case-control and cohort studies, yet direct comparisons of their performance using the same population, data sources, and analytic strategies remain rare. This study compares these two designs within a national population using harmonized analytic approaches. METHODS: Nationwide, matched test-negative case-control and retrospective cohort studies were conducted in Qatar between 1 January 2021 and 18 December 2021 to assess the effectiveness of the coronavirus disease (COVID-19) primary series of BNT162b2 and mRNA-1273 against any severe acute respiratory syndrome coronavirus 2 infection, symptomatic infection, and severe COVID-19. RESULTS: In the test-negative design, BNT162b2 effectiveness was 71.0% [95% confidence interval (CI): 70.1-71.9] against any infection, 75.6% (95% CI: 74.2-77.0) against symptomatic infection, and 96.3% (95% CI: 95.2-97.2) against severe COVID-19. In the cohort design, after adjustment for testing rate, corresponding effectiveness was 78.0% (95% CI: 77.1-78.9), 81.2% (95% CI: 79.8-82.5), and 98.0% (95% CI: 96.6-98.8), respectively. Both designs demonstrated similar, rapid, and largely linear waning of effectiveness in both magnitude and pattern. Test-negative design estimates lay between cohort estimates with and without adjustment for testing rate. Similar results were observed for mRNA-1273. CONCLUSIONS: Both designs yielded consistent effectiveness estimates across vaccines and clinically relevant outcomes, with only modest differences related to handling of health-seeking behavior. These findings demonstrate that, when rigorously implemented using quality data and harmonized analytic strategies, both designs produce comparable effectiveness estimates.
引用
- Sukik L, Paul P, Ayoub HH, et al. Evaluating COVID-19 vaccine effectiveness across epidemiologic designs: test-negative case-control versus retrospective cohort analyses in a nationwide study. Int J Epidemiol. 2026. PMID: 42772774. doi:10.1093/ije/dyag210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。